Matthias Saar1, Johannes Linxweiler2, Angelika Borkowetz3, Sebastian Fussek4, Katerina Urbanova5, Laura Bellut6, Glen Kristiansen7, Bernd Wullich6. 1. Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany, matthias.saar@uks.eu. 2. Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. 3. Department of Urology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 4. Department of Urology, University Hospital Greifswald, Greifswald, Germany. 5. Department of Urology, St. Antonius Hospital Gronau, Gronau, Germany. 6. Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 7. Institute of Pathology, University of Bonn Medical School, Bonn, Germany.
Abstract
INTRODUCTION: Multiparametric MRI (mpMRI) and MRI targeted biopsies (MRtb) are a new standard in prostate cancer (PCa) screening and diagnosis. Guidelines already include this approach for patients at risk. We aimed to gather information from German urologists about their knowledge, routine use, and attitude toward mpMRI and consecutive biopsy methods. MATERIALS AND METHODS: An anonymous online questionnaire was sent via Survey Monkey to the members of the German Society of Urology (DGU). Statistical analyses were performed using SPSS version 25.0. RESULTS: 496 members with a median age of 48.6 years (±11.7) participated in the survey. The majority rated mpMRI of the prostate as a very useful diagnostic tool (72.7%). MRtb of the prostate was considered as very advantageous (71.5%). MpMRI was used by 95.9%, and 83.2% also recommended MRtb predominantly in clinical institutions. For targeted biopsy, MRI-ultrasound fusion biopsy was clearly favored (75.8%). MpMRI was mostly used in patients with previously negative biopsy (90.9%) and in patients under active surveillance (60.9%). Arguments against the use of prostate mpMRI are costs (84.9%) and/or lack of sufficient radiological infrastructure (17.4%). CONCLUSION: Our data illustrate the meanwhile high acceptance and clinical use of the prostate mpMRI and MRtb in Germany.
INTRODUCTION: Multiparametric MRI (mpMRI) and MRI targeted biopsies (MRtb) are a new standard in prostate cancer (PCa) screening and diagnosis. Guidelines already include this approach for patients at risk. We aimed to gather information from German urologists about their knowledge, routine use, and attitude toward mpMRI and consecutive biopsy methods. MATERIALS AND METHODS: An anonymous online questionnaire was sent via Survey Monkey to the members of the German Society of Urology (DGU). Statistical analyses were performed using SPSS version 25.0. RESULTS: 496 members with a median age of 48.6 years (±11.7) participated in the survey. The majority rated mpMRI of the prostate as a very useful diagnostic tool (72.7%). MRtb of the prostate was considered as very advantageous (71.5%). MpMRI was used by 95.9%, and 83.2% also recommended MRtb predominantly in clinical institutions. For targeted biopsy, MRI-ultrasound fusion biopsy was clearly favored (75.8%). MpMRI was mostly used in patients with previously negative biopsy (90.9%) and in patients under active surveillance (60.9%). Arguments against the use of prostate mpMRI are costs (84.9%) and/or lack of sufficient radiological infrastructure (17.4%). CONCLUSION: Our data illustrate the meanwhile high acceptance and clinical use of the prostate mpMRI and MRtb in Germany.
Authors: Laura Bukavina; Jon C Tilburt; Badrinath Konety; Nilay D Shah; Cary P Gross; James B Yu; Frederick Schumacher; Alexander Kutikov; Marc C Smaldone; Simon P Kim Journal: Eur Urol Focus Date: 2018-09-13
Authors: Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan Journal: Nat Rev Urol Date: 2019-07-17 Impact factor: 14.432
Authors: Annerleim Walton Diaz; Nabeel Ahmad Shakir; Arvin K George; Soroush Rais-Bahrami; Baris Turkbey; Jason T Rothwax; Lambros Stamatakis; Cheng William Hong; Mohummad Minhaj Siddiqui; Chinonyerem Okoro; Dima Raskolnikov; Daniel Su; Joanna Shih; Hui Han; Howard L Parnes; Maria J Merino; Richard M Simon; Bradford J Wood; Peter L Choyke; Peter A Pinto Journal: Urol Oncol Date: 2015-03-06 Impact factor: 3.498
Authors: Benjamin Spilseth; Sangeet Ghai; Nayana U Patel; Samir S Taneja; Daniel J Margolis; Andrew B Rosenkrantz Journal: AJR Am J Roentgenol Date: 2017-10-24 Impact factor: 3.959
Authors: Rebecca L Siegel; Stacey A Fedewa; Kimberly D Miller; Ann Goding-Sauer; Paulo S Pinheiro; Dinorah Martinez-Tyson; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-09-16 Impact factor: 508.702
Authors: Xiaosong Meng; Andrew B Rosenkrantz; Neil Mendhiratta; Michael Fenstermaker; Richard Huang; James S Wysock; Marc A Bjurlin; Susan Marshall; Fang-Ming Deng; Ming Zhou; Jonathan Melamed; William C Huang; Herbert Lepor; Samir S Taneja Journal: Eur Urol Date: 2015-06-22 Impact factor: 20.096
Authors: Giorgio Gandaglia; Peter Albers; Per-Anders Abrahamsson; Alberto Briganti; James W F Catto; Christopher R Chapple; Francesco Montorsi; Nicolas Mottet; Monique J Roobol; Jens Sønksen; Manfred Wirth; Hendrik van Poppel Journal: Eur Urol Date: 2019-05-12 Impact factor: 20.096
Authors: Christopher P Filson; Shyam Natarajan; Daniel J A Margolis; Jiaoti Huang; Patricia Lieu; Frederick J Dorey; Robert E Reiter; Leonard S Marks Journal: Cancer Date: 2016-01-07 Impact factor: 6.860
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Emily A Vertosick; Stephen Zappala; Sanoj Punnen; Jonas Hugosson; Stephen A Boorjian; Alexander Haese; Peter Carroll; Matthew Cooperberg; Anders Bjartell; Hans Lilja; Andrew J Vickers Journal: Urology Date: 2021-08-24 Impact factor: 2.649
Authors: Mike Wenzel; Felix Preisser; Clarissa Wittler; Benedikt Hoeh; Peter J Wild; Alexandra Tschäbunin; Boris Bodelle; Christoph Würnschimmel; Derya Tilki; Markus Graefen; Andreas Becker; Pierre I Karakiewicz; Felix K H Chun; Luis A Kluth; Jens Köllermann; Philipp Mandel Journal: Diagnostics (Basel) Date: 2021-05-15